Scientists Investigating Alzheimer’s Drug Faulted in Leaked Reportnews2023-10-14T17:25:41+00:00October 14th, 2023|The New York Times|
New Study Finds Alzheimer’s Drug Donanemab Can Modestly Slow Memory Declinenews2023-07-17T14:30:32+00:00July 17th, 2023|The New York Times|
Leqembi: lo que hay que saber sobre el fármaco contra el alzhéimernews2023-07-08T11:00:12+00:00July 8th, 2023|The New York Times|
What to Know About Leqembi, the Alzheimer’s Drug Approved by the FDAnews2023-07-06T22:20:07+00:00July 6th, 2023|The New York Times|
FDA Makes Alzheimer’s Drug Leqembi Widely Accessiblenews2023-07-06T21:26:16+00:00July 6th, 2023|The New York Times|
Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Diseasenews2023-05-03T21:57:13+00:00May 3rd, 2023|The New York Times|
FDA Approves, Leqembi, New Treatment for Early Alzheimer’snews2023-01-06T22:58:48+00:00January 6th, 2023|The New York Times|
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogennews2022-12-29T19:54:35+00:00December 29th, 2022|The New York Times|
Alzheimer’s APOE4 Genetic Risk Targeted in Promising Trialnews2022-12-02T21:55:07+00:00December 2nd, 2022|The New York Times|
Alzheimer’s Drug May Benefit Some Patients, New Data Showsnews2022-11-30T00:50:06+00:00November 30th, 2022|The New York Times|
